Evidence map›Paper›PMID 38372795›Full record

ArticleApplied microbiology and biotechnology2024

Advanced detection of cervical cancer biomarkers using engineered filamentous phage nanofibers.

Xu Zhou, Yicun Wang, Meijing Bao, Yuqing Chu, Ruixue Liu, Qi Chen, Yang Lin

Open access · goldAbstract read
In one paragraph

Article in Applied microbiology and biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.8field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Biomaterials for biomarker imaging and detection.Journal of advanced research · 2026
    Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Xu ZhouDepartment of Obstetrics and Gynecology, The Second Hospital of Jilin University, 218 Ziqiang St, Changchun, 130041, Jilin, China.
Yicun Wang *Jilin Provincial Key Laboratory On Molecular and Chemical Genetic, The Second Hospital of Jilin University, 218 Ziqiang St, Changchun, 130041, Jilin, China. wangyicun@jlu.edu.cn.ORCID http://orcid.org/0000-0001-6497-3387
Meijing BaoDepartment of Obstetrics and Gynecology, The Second Hospital of Jilin University, 218 Ziqiang St, Changchun, 130041, Jilin, China.
Yuqing ChuDepartment of Obstetrics and Gynecology, The Second Hospital of Jilin University, 218 Ziqiang St, Changchun, 130041, Jilin, China.
Ruixue LiuDepartment of Obstetrics and Gynecology, The Second Hospital of Jilin University, 218 Ziqiang St, Changchun, 130041, Jilin, China.
Qi ChenDepartment of Obstetrics and Gynecology, The Second Hospital of Jilin University, 218 Ziqiang St, Changchun, 130041, Jilin, China.
Yang Lin *Department of Obstetrics and Gynecology, The Second Hospital of Jilin University, 218 Ziqiang St, Changchun, 130041, Jilin, China. linyang@jlu.edu.cn.
Second Affiliated Hospital of Jilin University · CNJilin University · CN

Funding

Jilin Provincial Scientific and Technological Development Program 2022B35National Natural Science Foundation of China 82272146Natural Science Foundation of Jilin Province 20230204048YYNatural Science Foundation of Jilin Province 20230508067RC
6 · The paper itself

Abstract

Cervical cancer is a major global health concern, characterized by its high incidence and mortality rates. The detection of tumor markers is crucial for managing cancer, making treatment decisions, and monitoring disease progression. Vascular endothelial growth factor (VEGF) and programmed death-ligand 1 (PDL-1) are key targets in cervical cancer therapy and valuable biomarkers in predicting treatment response and prognosis. In this study, we found that combining the measurement of VEGF and soluble PDL-1 can be used for diagnosing and evaluating the progression of cervical cancer. To explore a more convenient approach for detecting and assessing cervical cancer, we designed and prepared an engineered fd bacteriophage, a human-safe viral nanofiber, equipped with two peptides targeting VEGF and PD-L1. The dual-display phage nanofiber specifically recognizes and binds to both proteins. Utilizing this nanofiber as a novel capture agent, we developed a new enzyme-linked immunosorbent assay (ELISA) method. This method shows significantly enhanced detection sensitivity compared to conventional ELISA methods, which use either anti-VEGF or anti-PD-L1 antibodies as capture agents. Therefore, the phage dual-display nanofiber presents significant potential in detecting cancer markers, evaluating medication efficacy, and advancing immunotherapy drug development. KEY POINTS: • The combined measurement of VEGF and soluble Programmed Death-Ligand 1(sPD-L1) demonstrates an additive effect in the diagnosis of cervical cancer. Fd phage nanofibers have been ingeniously engineered to display peptides that bind to VEGF and PD-L1, enabling the simultaneous detection of both proteins within a single assay • Genetically engineered phage nanofibers, adorned with two distinct peptides, can be utilized for the diagnosis and prognosis of cancer and can be mass-produced cost-effectively through bacterial infections • Employing dual-display fd phage nanofibers as capture probes, the phage ELISA method exhibited significantly enhanced detection sensitivity compared to traditional sandwich ELISA. Furthermore, phage ELISA facilitates the detection of a single protein or the simultaneous detection of multiple proteins, rendering them powerful tools for protein analysis and diagnosis across various fields, including cancer research.

Indexed as

InovirusNanofibersUterine Cervical NeoplasmsB7-H1 AntigenBacteriophage M13Biomarkers, TumorFemaleHumansLigandsVascular Endothelial Growth Factor AB7-H1 AntigenBiomarkers, TumorLigandsVascular Endothelial Growth Factor ACancer diagnosisCervical cancerDiagnostic vectorNanofiberPhage

Identifiers

PMID38372795
PMCPMC10876719
OpenAlexW4391945938

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.